STAT+: Pharmalittle: We’re reading about CVS plans to split up, FDA inspections in India and China and more
The Trump administration will survey key components of pharmaceutical production in order to identify domestic supply chain vulnerabilities.
Morning, and welcome to the middle of the week. Remember, there are just a few more days until the weekend arrives. While pondering your weekend options, we invite you to join us for a needed caffeine boost. Our choice for today is maple bourbon - a shot of salvation.
In the world of healthcare industry giants, CVS Health has decided to split in two. This reversal of a signature deal aims to address the era of health industry consolidation. The split will create one company for Aetna and Caremark, while the other houses CVS's 9,000 retail pharmacies. The plan is set for early 2028.
Meanwhile, the U.S. Food and Drug Administration has increased unannounced drug inspections in India and China. This effort is part of an overall strategy to achieve inspection parity between domestic and international facilities. In FY 2026, the percentage of unannounced inspections in India rose from 47% to 87%, while in China, they increased from 19% to 61%. For the full story, continue reading at STAT+.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
